Description: <b>Cyclopamine</b> is a natural steroidal alkaloid derived from the corn lily, Veratrum californicum, which specifically disrupts the Hh signaling pathway.<br>
<p><b>Cyclopamine</b> — Cyclopamine is a natural steroidal alkaloid Hedgehog pathway antagonist derived from the corn lily <i>Veratrum californicum</i>. It is formally a small-molecule phytochemical / steroidal alkaloid and experimental Smoothened inhibitor. Cyclopamine is best treated as a preclinical tool compound and pharmacologic scaffold rather than a clinically deployed anticancer drug, because systemic translation is constrained by poor solubility, acid instability, limited pharmacokinetics, and developmental toxicity risk.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Direct Smoothened inhibition with downstream suppression of canonical Hedgehog signaling and GLI transcriptional output.</li>
<li>Suppression of Hedgehog-dependent cancer cell proliferation, survival, tumor growth, invasion, and metastatic behavior in susceptible models.</li>
<li>Inhibition or reversal of epithelial-mesenchymal transition programs, including reduced GLI1, Snail, Twist, and N-cadherin with increased E-cadherin in context-dependent models.</li>
<li>Reduction of cancer stem-like or tumor-initiating phenotypes where Hedgehog signaling maintains stemness or stromal tumor support.</li>
<li>Secondary noncanonical effects, including Wnt beta-catenin pathway suppression and mitochondrial respiration impairment in some models.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Cyclopamine has poor aqueous solubility, acid-sensitive conversion to less active products under gastric-like conditions, and suboptimal systemic pharmacokinetics. These constraints explain why clinically used Hedgehog inhibitors are synthetic SMO inhibitors or derivatives rather than cyclopamine itself.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many in-vitro studies use micromolar cyclopamine concentrations, often exceeding what is realistically attractive for systemic exposure with the parent compound. Interpretation should therefore distinguish pathway-probe activity from clinically achievable drug exposure. The compound is concentration-driven, not field-based or device-based.</p>
<p><b>Clinical evidence status:</b> Preclinical tool compound. Cyclopamine has strong mechanistic and animal-model evidence for Hedgehog pathway inhibition, but it is not an approved anticancer drug and has not become a standard clinical intervention. Clinical translation of this mechanism is represented by approved SMO inhibitors such as vismodegib, sonidegib, and glasdegib, not by cyclopamine itself.</p>
<h3>Cyclopamine cancer mechanism table</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SMO Hedgehog GLI axis</td>
<td>SMO signaling ↓; GLI1 ↓; PTCH1 output ↓</td>
<td>Developmental and progenitor Hedgehog signaling ↓</td>
<td>R/G</td>
<td>Core pathway blockade</td>
<td>Most central and most reproducible mechanism. Relevant mainly in tumors with ligand-dependent Hedgehog activity, PTCH loss, SMO activation, or Hedgehog-dependent stromal support.</td>
</tr>
<tr>
<td>2</td>
<td>Proliferation and cell cycle control</td>
<td>Proliferation ↓; G1 arrest ↑; tumor growth ↓</td>
<td>Normal proliferating progenitor activity may ↓</td>
<td>G</td>
<td>Growth suppression</td>
<td>Observed across multiple preclinical cancer models, but magnitude depends on Hedgehog dependency and concentration.</td>
</tr>
<tr>
<td>3</td>
<td>EMT invasion and metastasis</td>
<td>EMT ↓; invasion ↓; migration ↓; metastasis ↓</td>
<td>Context-dependent effects on wound repair and developmental motility programs</td>
<td>G</td>
<td>Anti-invasive shift</td>
<td>Mechanistically linked to GLI1 and EMT transcription factors. Direction aligns with E-cadherin ↑ and N-cadherin, Snail, or Twist ↓ in selected models.</td>
</tr>
<tr>
<td>4</td>
<td>Cancer stem-like signaling</td>
<td>Self-renewal and tumor-initiating phenotype ↓</td>
<td>Normal stem or progenitor Hedgehog support may ↓</td>
<td>G</td>
<td>Stemness suppression</td>
<td>Important in tumors where Hedgehog signaling maintains cancer stem-like compartments or therapy-resistant subpopulations.</td>
</tr>
<tr>
<td>5</td>
<td>Stromal tumor support</td>
<td>Paracrine tumor support ↓ in some models</td>
<td>Stromal repair and tissue homeostasis may be altered</td>
<td>G</td>
<td>Microenvironment modulation</td>
<td>Therapeutic leverage is context-dependent. In pancreatic cancer, later clinical experience with Hedgehog inhibition showed that stromal effects can be complex and not uniformly beneficial.</td>
</tr>
<tr>
<td>6</td>
<td>Wnt beta-catenin crosstalk</td>
<td>Beta-catenin TCF transcription ↓; E-cadherin ↑</td>
<td>Context-dependent epithelial homeostasis effects</td>
<td>G</td>
<td>Secondary pathway suppression</td>
<td>Reported in colorectal cancer models. Best interpreted as downstream or pathway-crosstalk biology rather than the primary drug target.</td>
</tr>
<tr>
<td>7</td>
<td>Mitochondrial respiration</td>
<td>Aerobic respiration ↓; mitochondrial function ↓</td>
<td>Potential mitochondrial stress in normal cells</td>
<td>R/G</td>
<td>Secondary bioenergetic stress</td>
<td>Reported especially with cyclopamine tartrate. This may contribute to cytotoxicity but is not the canonical defining mechanism.</td>
</tr>
<tr>
<td>8</td>
<td>Chemosensitization and radiosensitization</td>
<td>Therapy resistance programs ↓ in Hedgehog-dependent contexts</td>
<td>Normal-tissue effects uncertain</td>
<td>G</td>
<td>Adjunctive sensitization potential</td>
<td>Preclinical rationale exists through Hedgehog and GLI suppression, but parent cyclopamine is not clinically established as an adjunct.</td>
</tr>
<tr>
<td>9</td>
<td>Clinical Translation Constraint</td>
<td>In-vitro potency does not reliably translate to systemic therapy</td>
<td>Teratogenic and developmental pathway risk is high</td>
<td>G</td>
<td>Translation limitation</td>
<td>Poor solubility, acid instability, PK limitations, and developmental toxicity make cyclopamine mainly a research compound and scaffold for better SMO inhibitors.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min</p>
<p>R: 30 min–3 hr</p>
<p>G: >3 hr</p>